Neurocrine Biosciences
NBIX
$131.76
Share price
-0.58%
Change (1 day)
27.04%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
Neurocrine Biosciences (NBIX) Fails to deliver data
Key failure to deliver metrics for Neurocrine Biosciences :
- Last SEC data release: 2024-03-28
- Last 15 days FTD volume: $0.03 M
- Last 3 months FTD volume: $15.59 M
- Last year FTD volume: $35.11 M
Failures to deliver for Neurocrine Biosciences (NBIX) - 3 months history
Number of shares, 3 months chartBiweekly Failures to deliver volume for Neurocrine Biosciences (NBIX) - since 2013
Volume in USD (price x number of shares), data since 2013Neurocrine Biosciences (NBIX) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2024 | $15.55 M | -29.02% |
| 2023 | $21.91 M | -32.24% |
| 2022 | $32.34 M | -26.75% |
| 2021 | $44.16 M | 193.08% |
| 2020 | $15.06 M | -65.24% |
| 2019 | $43.34 M | -3.16% |
| 2018 | $44.76 M | -18.56% |
| 2017 | $54.96 M | 78.43% |
| 2016 | $30.8 M | 53.41% |
| 2015 | $20.07 M | 66.9% |
| 2014 | $12.03 M | 241.08% |
| 2013 | $3.52 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3months) | FTD volume (1 year) | Country |
|---|---|---|---|
 Pfizer PFE | $31.87 M | $0.32 B | 🇺🇸 USA |
 AbbVie ABBV | $8.76 M | $0.15 B | 🇺🇸 USA |
 Eli Lilly LLY | $50.92 M | $0.12 B | 🇺🇸 USA |
 Repligen
RGEN | $8.5 M | $0.10 B | 🇺🇸 USA |
 Athersys ATHX | $0.09 M | $0.71 M | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | $0.15 M | $1.23 M | 🇺🇸 USA |
 Palatin Technologies PTN | $1.01 M | $1.27 M | 🇺🇸 USA |
 Royalty Pharma RPRX | $1.77 M | $19.5 M | 🇬🇧 UK |